Research ExplorerPublicationsApolipoprotein A-I and risk for cardiovascular diseases

Apolipoprotein A-I and risk for cardiovascular diseases

Standard

Apolipoprotein A-I and risk for cardiovascular diseases. / Khuseyinova, Natalie; Koenig, Wolfgang.

In: CURR ATHEROSCLER REP, Vol. 8, No. 5, 09.2006, p. 365-373.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Khuseyinova, N & Koenig, W 2006, 'Apolipoprotein A-I and risk for cardiovascular diseases', CURR ATHEROSCLER REP, vol. 8, no. 5, pp. 365-373. https://doi.org/10.1007/s11883-006-0033-9

APA

Khuseyinova, N., & Koenig, W. (2006). Apolipoprotein A-I and risk for cardiovascular diseases. CURR ATHEROSCLER REP, 8(5), 365-373. https://doi.org/10.1007/s11883-006-0033-9

Vancouver

Khuseyinova N, Koenig W. Apolipoprotein A-I and risk for cardiovascular diseases. CURR ATHEROSCLER REP. 2006 Sep;8(5):365-373. https://doi.org/10.1007/s11883-006-0033-9

Bibtex

@article{63b091f7b0b94ce688c0d85fd6330d81,
title = "Apolipoprotein A-I and risk for cardiovascular diseases",
abstract = "Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport. More recently, it has been suggested that apolipoprotein A-I (apoA-I), the major protein component of HDL, possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease. This makes apoA-I a very attractive biomarker candidate for implementation into clinical practice, taking into account its analytical advantages. This review summarizes our current knowledge based on observations from recent studies, with emphasis on potential pathophysiologic mechanisms of action and on the clinical utility of apoA-I as a predictor of cardiovascular risk.",
keywords = "Apolipoprotein A-I/blood, Cardiovascular Diseases/blood, Humans, Prognosis, Risk Factors",
author = "Natalie Khuseyinova and Wolfgang Koenig",
year = "2006",
month = sep,
doi = "10.1007/s11883-006-0033-9",
language = "English",
volume = "8",
pages = "365--373",
journal = "CURR ATHEROSCLER REP",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "5",

}

RIS

TY - JOUR

T1 - Apolipoprotein A-I and risk for cardiovascular diseases

AU - Khuseyinova, Natalie

AU - Koenig, Wolfgang

PY - 2006/9

Y1 - 2006/9

N2 - Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport. More recently, it has been suggested that apolipoprotein A-I (apoA-I), the major protein component of HDL, possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease. This makes apoA-I a very attractive biomarker candidate for implementation into clinical practice, taking into account its analytical advantages. This review summarizes our current knowledge based on observations from recent studies, with emphasis on potential pathophysiologic mechanisms of action and on the clinical utility of apoA-I as a predictor of cardiovascular risk.

AB - Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport. More recently, it has been suggested that apolipoprotein A-I (apoA-I), the major protein component of HDL, possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease. This makes apoA-I a very attractive biomarker candidate for implementation into clinical practice, taking into account its analytical advantages. This review summarizes our current knowledge based on observations from recent studies, with emphasis on potential pathophysiologic mechanisms of action and on the clinical utility of apoA-I as a predictor of cardiovascular risk.

KW - Apolipoprotein A-I/blood

KW - Cardiovascular Diseases/blood

KW - Humans

KW - Prognosis

KW - Risk Factors

U2 - 10.1007/s11883-006-0033-9

DO - 10.1007/s11883-006-0033-9

M3 - SCORING: Review article

C2 - 16901406

VL - 8

SP - 365

EP - 373

JO - CURR ATHEROSCLER REP

JF - CURR ATHEROSCLER REP

SN - 1523-3804

IS - 5

ER -